Paris, France, Jan 24, 2025 – The Paris Saclay Cancer Cluster (PSCC) is proud to announce the selection of three new innovative oncology projects, bringing the total number of supported projects to 61. These bold and visionary initiatives exploit cutting-edge technologies to tackle the most complex challenges in cancer care. https://www.parissaclaycancercluster.org/projets-accompagnes
Among these projects is Oncovita, a biotech company developing a disruptive technology based on a genetically modified live attenuated measles vaccine. Its main candidate, MVdeltaC, is an oncolytic virus inducing immunogenic cell death, with promising preclinical results. Clinical trials for pleural mesothelioma and triple-negative breast cancer are planned for 2026.
« It’s a great opportunity to be part of Europe’s largest oncology cluster, and to benefit from the multidisciplinary support of the PSCC. This makes all the more sense as we are due to start our clinical trial for our MVdeltaC candidate in 2026 at Gustave Roussy, Europe’s leading cancer center, which is largely associated with the PSCC platform », emphasizes Stéphane Altaba, CEO of Oncovita.
The PSCC is a biocluster of European scope and international ambition, selected by the French government as part of the France 2030 plan, whose mission is to accelerate innovation in oncology.